Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.

Clinical and translational radiation oncology·2026
Same author

The French Reirradiation Team for Research and Treatment (FReTREAT): A national collaborative model by Unitrad for advancing reirradiation research, education, and clinical practice in France.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same author

Syndrome of pleural and retrosternal "bridging" fibrosis and retroperitoneal fibrosis in patients with asbestos exposure.

BMJ case reports·2025
Same author

What are the outcomes for long-term survivors after esophagectomy ? - Evidence from a randomized controlled trial (FFCD9901).

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Efficacy and Toxicity of (Chemo)Radiation Therapy in HIV+ Patients with Squamous Cell Anal Cancer, a Subgroup Analysis of the National Multicenter Cohort FFCD-ANABASE.

International journal of radiation oncology, biology, physics·2024
Same author

Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2023

Related Experiment Video

Updated: Jun 27, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Thymoma: a focus on current therapeutic management.

Nicolas Girard1, Françoise Mornex, Paul Van Houtte

  • 1Department of Radiotherapy, Lyon-Sud Hospital, Université de Lyon, Lyon, France.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|December 20, 2008
PubMed
Summary

Complete surgical resection is crucial for thymoma management and prognosis. Adjuvant therapies like radiotherapy and chemotherapy are used for advanced or incompletely resected thymomas, improving outcomes.

Related Experiment Videos

Last Updated: Jun 27, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Pathology

Background:

  • Thymomas are rare malignant tumors of the thymus.
  • The Masaoka classification is the standard staging system.
  • Surgery is the primary treatment modality for thymomas.

Purpose of the Study:

  • To review the current management strategies for thymomas.
  • To highlight the prognostic significance of complete tumor resection.
  • To discuss the role of adjuvant therapies and multimodal approaches.

Main Methods:

  • Review of existing literature on thymoma management.
  • Analysis of surgical, pathological, and therapeutic data.
  • Discussion of multimodal treatment strategies for unresectable thymomas.

Main Results:

  • Complete surgical resection is the most significant prognostic factor for survival.
  • Postoperative radiotherapy improves outcomes in incompletely resected thymomas and may reduce recurrence in completely resected Stage II and III tumors.
  • Multimodal therapy, including neoadjuvant chemotherapy and surgery, is essential for unresectable thymomas.

Conclusions:

  • Thymoma management requires a multidisciplinary approach involving surgeons, oncologists, and pathologists.
  • Complete resection is paramount for favorable prognosis.
  • Further collaborative studies are needed to optimize treatment strategies, incorporating advancements like robotic surgery and novel therapies.